Skip to main content

Dharmacon to Provide siRNAs to Bayer

NEW YORK, Nov. 10 (GenomeWeb News) - Dharmacon said today that it has signed an agreement to provide custom siRNA reagents to Bayer for use in target validation and drug development projects.


Financial terms of the arrangment were not disclosed.


Dharmacon has recently struck a number of similar deals with other drugmakers, including Abbott, Exelixis, and Odyssey Thera.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.